Virtual Reality for Coping With Involuntary Early Pregnancy Loss
NCT ID: NCT05880381
Last Updated: 2025-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
20 participants
INTERVENTIONAL
2023-05-01
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main goals of this study are:
1. Evaluate the impact of the proposed VR paradigm in women who suffered a gestational loss in the first 20 weeks of gestation, compared to a control group that follows the usual standard care;
2. Evaluate the usability, user experience, and acceptance of the proposed approach.
Participants in the VR group will have an intervention program lasting four weeks, with 3 weekly sessions of 45-60 minutes, using the developed prototype.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
E-health Intervention for Improving Mental Health During Pregnancy Using Virtual Reality
NCT05756205
Virtual Reality Experience in First Trimester D&C
NCT03533036
VR Headset for Pain During Pregnancy Termination
NCT06029582
Virtual Reality in MVA for Miscarriage
NCT04466956
Virtual Reality to Improve Low-back Pain and Pelvic Pain During Pregnancy
NCT05571358
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The present research study aims to evaluate the feasibility of a psychological VR-based approach in a controlled pilot study with 20 women who suffered an early gestational loss in the last 6 months. Using the developed prototype, the experimental VR group will have an intervention program lasting four weeks, with 3 weekly sessions of 45-60 minutes.
The investigators aimed to verify if the use of the proposed VR paradigm will significantly reduce symptoms of grief, depression, anxiety and post-traumatic stress, and that this reduction will be significantly greater compared to the control group.
The study proposed is very innovative in terms of the target population and the use of VR, specifically designed to address gestational loss. In addition, it opens a new avenue of research on a topic that is still silenced and considered taboo in society. Thus, this interdisciplinary research has an expected scientific, technological, and social impact, namely: 1) contributes to a better understanding of the process of psychological recovery after an early gestational loss; 2) contributes to the advancement of technologies aimed at psychological support; 3) has the potential to accelerate the resolution of grief by bringing emotional and psychological support to women who do not have access to other means of support; and 4) contributes to reducing the economic burden on health care by providing tools to improve the well-being of patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Virtual Reality Group
Patients allocated to the treatment group will undergo an intervention that comprises 3 weekly sessions of 60 minutes for 4 weeks with the VR prototype.
Virtual Reality Group
Patients allocated to the treatment group will undergo an intervention that comprises 3 weekly sessions of 60 minutes for 4 weeks with the VR prototype.
Control Group
The participants allocated to this group will do the formal standard care provided by the Gynecology- Obstetric service.
Control Group
The participants allocated to this group will do the formal standard care provided by the Gynecology- Obstetric service.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Virtual Reality Group
Patients allocated to the treatment group will undergo an intervention that comprises 3 weekly sessions of 60 minutes for 4 weeks with the VR prototype.
Control Group
The participants allocated to this group will do the formal standard care provided by the Gynecology- Obstetric service.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* having a diagnosis of mental disorder,
* undergoing any psychological intervention,
* vision impairments that could interfere with the execution of the VR tasks.
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundação para a Ciência e a Tecnologia
OTHER
Serviço de Saúde da Região Autónoma da Madeira- SESARAM
UNKNOWN
Universidade da Madeira
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mónica Cameirão
Assistant Professor and researcher at the University of Madeira
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universidade da Madeira
Funchal, , Portugal
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07/2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.